I received this in a letter from a former board member of the Multiple Sclerosis Center of Atlanta. I am posting it with his permission. (Edited to protect personal information)

For those of you who go to this center, you may be interested in what he got for stats there.


This is his disclaimer:

"The stats were not compiled from a format that lends itself well to publication for statistical analysis. Patient records were not set up on the computer in the same fashion that would be used in an FDA study.
The numbers were provided to me directly by the head of infusion operations at MSCA and were from his personal compilations over time and made at my request.
The numbers/statistics were discussed at a recent meeting of MSCA's Board, of which I am a recent member"


"The Multiple Sclerosis Center of Atlanta [MSCA] has the largest concentration of MS patents in the world. Currently, there are nearly 4,000 MS patients treated there. The MSCA is a non-profit treatment, research, educational and support group for MS patients, along with some other neuro work, including Alzheimer's.

Currently, the MSCA has just over 500 patients on Tysabri, more than 20% of their eligible RRMS patients. This number continues to grow steadily in both % and total numbers. The MSCA's protocol for screening patients and follow up for those goes beyond the typical MS practice in scope and detail resulting in some significant tracking of those on Tysabri.

Since the MSCA was involved with the initial Tysabri trials before {it was withdrawn from market} and was among the first few groups registered for TOUCH, it has had considerable experience with Tysabri patients who have been on the drug for 18 to 48 months.


During this time:

-NO PATIENT HAS HAD A DECLINE IN THEIR MS CONDITION

-1/3rd of the patients have remained stable

-2/3rds of the patients have had a MATERIAL improvement in their symptoms, including improved mobility, balance, vision, energy and cognitive function.

-The virtual elimination of new lesions AND substantial eradication of existing lesions has been consistent with the growing evidence of symptomatic improvements

-Only a few [less than 6] have had allergic or other reactions which resulted in their dropping out of Tysabri treatment and several have dropped treatment due to copay difficulties."

I will continue to provide information as I receive it.

Good Luck Everyone!